


### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Claims:**

What is claimed is:

1. (Original): A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(1)

wherein:

$R^1$  represents  $-C_{1-6}$  alkyl substituted by one or more (e.g. 1, 2 or 3) halogen or cyano groups,  $-C_{0-4}$  alkyl- $C_{3-8}$ cycloalkyl,  $-C_{2-4}$  alkoxy- $C_{1-4}$  alkyl,  $-C_{1-4}$  alkyl-aryl,  $-C_{1-4}$  alkyl-heteroaryl or  $-C_{0-4}$  alkyl-heterocyclyl;

wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl groups of R<sup>1</sup> may be optionally substituted by one or more (e.g. 1, 2 or 3) halogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, cyano, amino or trifluoromethyl groups:

$R^2$  represents hydrogen or  $C_{1-6}$  alkyl:

$m$  represents an integer from 1 to 4, such that when  $m$  is an integer greater than 1, two  $R^2$  groups may instead be linked to form a  $CH_2$ ,  $(CH_2)_2$  or  $(CH_2)_3$  group;

$R^3$ ,  $R^4$  and  $R^5$  independently represent hydrogen, halogen, cyano,  $-CF_3$ ,  $-CF_3O$ ,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkanoyl or a group  $-CONR^6R^7$ :

$R^6$  and  $R^7$  independently represent hydrogen or  $C_{1-6}$  alkyl or  $R^6$  and  $R^7$  together with the nitrogen to which they are attached may form a nitrogen containing heterocyclil or heteroaryl group:

$n$  represents an integer from 1 to 3.

p represents 1 or 2;

A represents an -aryl, -heteroaryl, -aryl-aryl, -aryl-heteroaryl, -heteroaryl-aryl or -heteroaryl-heteroaryl group;

wherein said aryl and heteroaryl groups of A may be optionally substituted by one or more (e.g. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C<sub>1-6</sub> alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C<sub>1-6</sub> alkoxy, aryLC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkoxyC<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> alkoxy carbonyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyloxy, C<sub>1-6</sub> alkylsulfonylC<sub>1-6</sub> alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylsulfonamido, C<sub>1-6</sub> alkylamido, C<sub>1-6</sub> alkylsulfonamidoC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylamidoC<sub>1-6</sub> alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC<sub>1-6</sub> alkyl, arylcarboxamidoC<sub>1-6</sub> alkyl, aroyl, aroylC<sub>1-6</sub> alkyl, aryLC<sub>1-6</sub> alkanoyl, or a group CONR<sup>8</sup>R<sup>9</sup> or SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, wherein R<sup>8</sup> and R<sup>9</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or R<sup>8</sup> and R<sup>9</sup> together with the nitrogen atom to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group;

or solvates thereof.

2. (Original): A compound of formula (I) as defined in claim 1 which is:  
8-(4-(4-Fluorobenzyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-Cyclopropylmethyl-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-(Cyclohexyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-Cyclopentyl-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-Cyclobutyl-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-Cyclopropyl-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-(2-methoxyethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;  
8-(4-(2,2,2-Trifluoroethyl)-piperazin-1-yl)-3-(4-fluoro)-phenylsulfonylquinoline;  
or a pharmaceutically acceptable salt thereof.

3. (Currently amended): A pharmaceutical composition which comprises a compound as defined in claim 1 or claim 2 and a pharmaceutically acceptable carrier or excipient.

Claims 4-7 (Cancelled).

8. (Currently amended): A method of treating depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound of formula (I) as defined in claim 1 ~~or claim 2~~ or a pharmaceutically acceptable salt thereof.